# TTC6 (Q-20): sc-242042



The Power to Question

#### **BACKGROUND**

The tetratricopeptide repeat (TPR) motif is a degenerate, 34 amino acid sequence found in many proteins and acts to mediate protein-protein interactions in various pathways. At the sequence level, there can be up to 16 tandem TPR repeats, each of which has a helix-turn-helix shape that stacks on other TPR repeats to achieve ligand binding specificity. TTC6 (tetratricopeptide repeat protein 6) is a 520 amino acid protein that contains 13 TPR repeats. The gene encoding TTC6 maps to human chromosome 14, which houses over 700 genes and comprises nearly 3.5% of the human genome. Chromosome 14 encodes the presinilin 1 (PSEN1) gene, which is one of the three key genes associated with the development of Alzheimer's disease (AD). The SERPINA1 gene is also located on chromosome 14 and, when defective, leads to the genetic disorder  $\alpha$ 1-antitrypsin deficiency, which is characterized by severe lung complications and liver dysfunction.

## **REFERENCES**

- Heilig, R., et al. 2003. The DNA sequence and analysis of human chromosome 14. Nature 421: 601-607.
- 2. Godbolt, A.K., et al. 2004. A presenilin 1 R278I mutation presenting with language impairment. Neurology 63: 1702-1704.
- Stolk, J., et al. 2006. α1-antitrypsin deficiency: current perspective on research, diagnosis, and management. Int. J. Chron. Obstruct. Pulmon. Dis. 1: 151-160.
- Vetrivel, K.S., et al. 2006. Pathological and physiological functions of presenilins. Mol. Neurodegener. 1: 4.
- 5. Albani, D., et al. 2007. Presenilin-1 mutation E318G and familial Alzheimer's disease in the Italian population. Neurobiol. Aging 28: 1682-1688.
- 6. Cruz, P.E., et al. 2007. The promise of gene therapy for the treatment of  $\alpha$ 1 antitrypsin deficiency. Pharmacogenomics 8: 1191-1198.
- Filley, C.M., et al. 2007. The genetics of very early onset Alzheimer disease. Cogn. Behav. Neurol. 20: 149-156.
- Martín-Subero, J.I., et al. 2007. A comprehensive genetic and histopathologic analysis identifies two subgroups of B-cell malignancies carrying a t(14;19)(q32;q13) or variant BCL3-translocation. Leukemia 21: 1532-1544.
- 9. Micci, F., et al. 2007. Molecular cytogenetic characterization of t(14;19) (q32;p13), a new recurrent translocation in B cell malignancies. Virchows Arch. 450: 559-565.

## **CHROMOSOMAL LOCATION**

Genetic locus: TTC6 (human) mapping to 14q21.1.

# SOURCE

TTC6 (Q-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of TTC6 of human origin.

## **STORAGE**

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

#### **PRODUCT**

Each vial contains 200  $\mu g$  lgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-242042 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## **APPLICATIONS**

TTC6 (0-20) is recommended for detection of TTC6 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for TTC6 siRNA (h): sc-92423, TTC6 shRNA Plasmid (h): sc-92423-SH and TTC6 shRNA (h) Lentiviral Particles: sc-92423-V.

Molecular Weight of TTC6: 49 kDa.

# **RECOMMENDED SECONDARY REAGENTS**

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat lgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat lgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat lgG-FITC: sc-2024 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

#### **RESEARCH USE**

For research use only, not for use in diagnostic procedures.

# **PROTOCOLS**

See our web site at www.scbt.com or our catalog for detailed protocols and support products.

**Santa Cruz Biotechnology, Inc.** 1.800.457.3801 831.457.3800 fax 831.457.3801 **Europe** +00800 4573 8000 49 6221 4503 0 **www.scbt.com**